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ESTUDI TOMOGRÀFIC DELS FOTORECEPTORS DE LA RETINA 
EN PACIENTS DIABÈTICS SENSE RETINOPATIA O AMB 
RETINOPATIA NO PROLIFERATIVA LLEU 
 
RESUM 
La retinopatia diabètica (DR) provoca alteracions microvasculars que condueixen a 
isquemia, alteració de la barrera hematorretiniana, neovascularització i edema 
macular. 
L'objectiu d'aquest estudi és analitzar les possibles alteracions dels fotoreceptors en 
els estadis inicials de la DR, i estudiar la seva influència en l'agudesa visual i la visió del 
color. 
Quaranta-quatre ulls de 44 diabètics tipus 2 sense DR o amb DR no proliferativa lleu es 
van comparar amb 44 ulls sans de 44 pacients. 
Es va avaluar l'agudesa visual, la visió del color, i mitjançant la OCT es va analitzar 
l'estat de les capes membrana limitant externa (ELM), unió del segment 
intern/segment extern (IS/OS) i el segment extern dels cons (COST), les cúpules ELM i 
IS/OS, el gruix macular central, i el gruix del complex intern de la retina nasal i 
temporal a 1000 i 2000µm del centre de la fòvea. 
Els resultats van mostrar una pèrdua significativa de les cúpules de ELM i IS/OS. El grup 
diabetis mellitus (DM) sense DR va mostrar una gruix significativament menor a 
1000µm del centre de la fòvea. Aquests ulls també van mostrar una menor agudesa 
visual quan la COST no era visible. 
En conclusió, hi ha evidències d’alteració dels fotoreceptors en els estadis inicials de la 
DR i poden estar relacionades amb la patogènesis de la DM. 
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ESTUDIO TOMOGRAFICO DE LOS FOTORRECEPTORES DE LA 
RETINA EN PACIENTES DIABETICOS SIN RETINOPATIA O CON 
RETINOPATIA NO PROLIFERATIVA LEVE 
 
RESUMEN 
La retinopatía diabética (DR) provoca alteraciones microvasculares que conducen a 
isquemia, alteración de la barrera hematorretiniana, neovasculairzación y edema 
macular. 
El objetivo de este estudio es analizar las posibles alteraciones de los fotorreceptores 
en los estadios iniciales de la DR, y estudiar su influencia en la agudeza visual y la visión 
del color. 
Cuarenta y cuatro ojos de 44 diabéticos tipo 2 sin DR o con DR no proliferativa leve se 
compararon con 44 ojos sanos de 44 pacientes. 
Se evaluó la agudeza visual, la visión del color, y mediante la OCT se analizó el estado 
de las capas membrana limitante externa (ELM), unión del segmento 
interno/segmento externo (IS/OS) y el segmento externo de los conos (COST), las 
cúpulas ELM e IS/OS, el grosor macular central, y el grosor del complejo interno de la 
fóvea nasal y temporal a 1000 y 2000µm del centro de la fóvea. 
Los resultados mostraron una pérdida significativa de las cúpulas ELM e IS/OS. El grupo 
diabetes mellitus (DM) sin DR mostró un grosor significativamente menor a 1000µm 
del centro de la fóvea. Estos ojos también mostraron una menor agudeza visual 
cuando la COST no era visible. 
En conclusión, hay evidencias de alteraciones en los fotorreceptores en los estadios 
iniciales de la DR y pueden estar relacionadas con la patogénesis de la DM. 
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TOMOGRAPHIC STUDY OF RETINAL PHOTORECEPTORS IN 
DIABETIC PATIENTS WITHOUT RETINOPATHY OR WITH MILD 
NON PROLIFERATIVE RETINOPHATY 
 
ABSTRACT 
Diabetic retinopathy (DR) causes alterations leading to ischemia, increased of blood-
retinal barrier, neovascularization and macular oedema. 
 
The aim of this study is to analyze the possible morphological changes of 
photoreceptors in the early stages of DR, and study their influence on visual acuity and 
colour vision. 
 
Forty-four eyes of 44 type 2 diabetics without DR or mild non proliferative DR were 
compared with 44 healthy eyes of 44 patients. 
 
Visual acuity and colour vision was evaluated, also by OCT the state of the external 
limiting membrane (ELM), inner segment / outer segment junction (IS/OS) and cone outer 
segment tips (COST) layers of the retina, the ELM and IS/OS dome-shaped, the central 
macular thickness, and the inner retinal complex thickness nasal and temporal was 
evaluated at 1000 and 2000µm from the centre of the fovea. 
 
The results showed a significant loss of ELM and IS/OS dome-shaped. The diabetes 
mellitus (DM) group without DR showed significantly lower thickness at 1000µm from 
the centre of the fovea. This eyes also displayed significantly lower visual acuity when 
COST were not visible. 
 
In conclusion, there are evidences of photoreceptor alterations in the early stages of 
DR and it may be related to the pathogenesis of DM. 
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COVER LETTER 
 
 
Dear Editor, 
 
Attached you will find the paper entitled "Tomographic study of retinal photoreceptors in 
diabetic patients without retinopathy or with mild non proliferative retinopathy", which we 
are submitting for publication in British Journal of Ophthalmology as an original article. 
 
To determinate the possible morphological changes of photoreceptors in the early stages of 
diabetic retinopathy, and study their influence on visual acuity and colour vision. The state of 
retinal layers by optical coherence tomography (OCT) were analysed, and compared with 
visual acuity and colour vision. 
 
We would be very grateful for any comments or suggestions you may wish to make. 
 
Thank you for your attention. 
 
Yours sincerely, 
 
 
Mireia Sánchez 
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ABSTRACT 
 
Background/aims: Diabetic retinopathy (DR) is a progressive condition resulting from diabetes 
mellitus, and is the leading cause of blindness in people of working age in developed 
countries. Our aim is to analyse foveal morphological changes, in diabetic patients without 
clinically manifested diabetic retinopathy, or at initial stages of this ocular disorder and to 
study the influence of these changes in visual acuity and colour vision. 
 
Methods: Forty-four eyes of 44 patients with type 2 diabetes mellitus without or with mild no 
proliferative DR were compared with 44 healthy eyes of 44 patients with similar age and sex.  
Visual acuity and colour vision was evaluated, also by optical coherence tomography (OCT) the 
state of the external limiting membrane (ELM), inner segment / outer segment junction 
(IS/OS) and cone outer segment tips (COST) layers of the retina, the dome-shaped appearance 
of ELM and IS/OS, the central macular thickness, and the nasal and temporal inner retinal 
complex thickness was evaluated at 1000 and 2000 µm from the centre of the fovea. 
 
Results: The results showed a significant loss of ELM IS/OS domes. COST distribution was 
similar in both groups. DM group without DR showed significantly lower IRCT thickness at 
1000 µm of the centre. This eyes also displayed significantly lower visual acuity when COST 
were not visible, compared to cases with unaltered COST. 
 
Conclusion: Photoreceptor alterations in the early stages of diabetic retinopathy may be 
related to the pathogenesis of diabetes mellitus. 
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MAIN TEXT 
 
INTRODUCTION 
 
American Diabetes Association1 defines, diabetes mellitus (DM) as a group of metabolic 
diseases characterized by hyperglycaemia resulting from defects in insulin secretion, insulin 
action or both. Chronic hyperglycaemia is associated with long-term damage, dysfunctions 
and failure of various organs, especially eye, kidney, nervous and cardiovascular systems. 
According to the aetiology, DM is divided mainly into two groups. The DM type 1 is caused by 
a deficiency of the absolute secretion of insulin while type 2 is caused by a combination of 
resistance to insulin action along with an inadequate compensatory insulin secretion. The 
latter is the most common type. It is estimated that by 2030 the number of people with 
diabetes will reach 366 million, 4.4% of the world population.2 
 
The chronic vascular complications affect especially the vision of patients. Ocular 
manifestations are: cataracts, diabetic macular oedema (DME) and diabetic retinopathy (DR). 
DR is a progressive condition with microvascular alterations that lead to retinal ischemia, an 
increased permeability of the blood-retinal barrier, retinal neovascularisation and macular 
oedema.3,4 DR5 can be proliferative and non-proliferative and its presence is determined by 
the appearance of changes in the fundus. Non-proliferative DR shows three degrees of 
intensity: mild, moderate and severe, depending on the severity and frequency of funduscopic 
alterations. 
 
Often, untreated patients with DR suffer severe visual loss.4 In developed countries DR is the 
leading cause of blindness in people of working age6 and has a considerable economic and 
social impact, especially in health systems. An appropriate management of patients with DR, it 
would save more than 90% of visual loss cases,7,8 it is extremely important to classify the 
severity of DR and to establish the appropriate therapy as soon as possible. 
 
Optical coherence tomography (OCT) is a technique commonly used in ophthalmology to 
evaluate retina state and to predict visual results. Its high resolution images allows analysing 
the different photoreceptor structures at foveal level, displayed as subcellular layers. In DME 
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cases OCT images show a disruption of the internal retina layers: external limiting membrane 
(ELM), photoreceptor inner segment / outer segment junction (IS/OS)  and a reduction in the 
length of the outer segment of the central foveal cones, as well as in some patients a serous 
neurosensory detachment.9,10 However, the photoreceptors role in the pathogenesis of DR 
has been largely overlooked, although these cells represent the majority of the mass and the 
metabolic activity of the retina.11 
 
There is some evidence, in animal studies, that point to involvement of photoreceptors in the 
origin of the RD.11 In addition, it was reported that the DR is less severe in retinitis pigmentosa 
patients,12 a disease that destroys photoreceptors. 
 
Currently, only two clinical studies have analyzed the involvement of photoreceptors in 
patients with different RD severity.9,13 Our group aims to analyse foveal morphological 
changes, in diabetic patients without clinically manifested DR, or at initial stages of this ocular 
disorder and to study the influence of these changes in visual acuity and colour vision. This 
new approach may improve DR early detection and minimize the effects that this condition 
leads to patient vision. 
 
 
MATERIALS AND METHODS 
 
Forty-four eyes of 44 patients with type 2 DM without or with mild no proliferative DR were 
compared with 44 healthy eyes of 44 patients with similar age and sex. Patients suffering from 
a disease that affects the blood vessels in the retina, who have retinal surgery or laser, retinal 
detachment or vitreous haemorrhage where excluded. Eyes with opacity obstacles to 
obtaining quality images with the OCT and patients with systemic inflammatory diseases 
(rheumatoid arthritis, asthma ...), neoplasm, dialysis, coronary artery disease, etc., were also 
excluded because high levels of vascular endothelial growth factor (VEGF) have been 
associated with alterations in outer retinal layers. Eyes that have been diagnosed and/or 
treated for different diseases that may cause macular thickening or poor delineation of foveal 
layers (macular oedema eyes with subretinal or intraretinal fluid, hard exudates, staphyloma 
with high myopia, venous occlusion, epiretinal membrane, vitreomacular traction, etc.) were 
also excluded. The study was approved by the Ethics Committee for Clinical Research of 
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Hospital de Terrassa-Consorci Sanitari de Terrassa, and all patients were informed and gave 
their written consent. 
 
First, the fundus under mydriasis was analyzed at the ophthalmological exploration to classify 
the type of RD. The ocular media were also explored and the intraocular pressure was 
measured with the Goldman tonometer. 
 
Optometric exploration included: a brief anamnesis, the best-corrected visual acuity (BCVA) 
with the Snellen optotype in decimal scale. Colour vision was evaluated with two specific 
tests: Ishihara and Farnsworth-Munsell D-15 (FM D-15) tests. Ishihara test is used to diagnose 
and classify the changes in colour vision, at the level of red-green axis. FM D-15 test identify 
the defect in colour vision; protanomaly (reduced sensitivity to red) deuteranomaly (reduced 
sensitivity to green) or tritanomaly (reduced sensitivity to blue). In both test, the number of 
errors were recorded. 
 
The study of the foveal morphology was carried out using a Cirrus HD-OCT 4000. (Carl Zeiss 
Meditec Inc., Dublin, CA; version 5.0.0). This is a non-invasive analysis that allows obtaining 
cross sections images of ocular tissues in vivo. This technique is widely used to study the fovea 
and optic nerve. OCT performs a picture with the macular cube scan mode to obtain data of 
central macular thickness and 5 lines raster scan allows classifying the state of the retina 
external layers. The ELM, IS/OS and cone outer segment tips (COST) layers were classified in 
three categories. If they were absent in the OCT image, were classified as category 0. If they 
were present as a dashed line, were classified as category 1. If they were as a continuous line, 
were classified as category 2. Also, presence/absence of ELM and IS/OS dome-shaped 
appearance due to the higher length of the central photoreceptors, also named foveal bulge 
(FB), was categorized and the central macular thickness was automatically measured in µm. In 
addition, the inner retinal complex thickness (IRCT) was measured, by a masked observer, 
from nerve fiber layer to inner nuclear layer, in nasal and temporal side, at 1000 (IRCT1) and 
2000 µm (IRCT2) from the centre of the fovea. 
 
Exploratory analysis of the studied variables was carried out. In order to analyze changes, 
student t test and Fisher’s exact test were used for interindividual comparisons between 
controls and DM group. Paired t-test was applied for intraindividual comparisons describing 
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IRCT differences in different locations of the same eye. SPSS V19 was used for statistical 
analysis and a significant level of p<0.05 was considered. Normal variable distribution was 
assessed with the Kolmogorov-Smirnov test. 
 
 
RESULTS 
 
Foveal description   
 
From the 44 eyes of 44 DM patients, 32 (73%) showed no DR and 12 (27%) were classified as 
mild no proliferative DR. The ELM and IS/OS layers in the three groups (control, no DR, and 
mild non-proliferative DR group) always showed cat 2. Table 1 illustrates distribution of COST 
category in the three groups. See figure 1 for typical examples of OCT foveal pattern. 
 
 
COST distribution 
Cat 0 Cat 1 Cat 2 
Control 6 (13%) 14 (32%) 24 (55%) 
DM without DR 6 (19%) 9 (28%) 17 (53%) 
DM with mild non-proliferative DR 5 (42%) 5 (42%) 2 (16%) 
 
Table 1. Distribution COST category in the three groups. 
 
 
 
Figure 1. Spectral domain optical coherence tomography (OCT) showing the foveal bulge (FB) 
categories. A and B showed category 2 at external limiting membrane (ELM), inner segment / 
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outer segment junction (IS/OS) and cone outer segment tips (COST). A shows presence of 
dome-shape appearance in both, ELM and IS/OS, and B shows absence of this foveal 
characteristics. 
 
ELM and IS/OS bulges were present in 32 (73%), and 42 (95%) healthy eyes, respectively, in 13 
(42%) and 21 (68%) eyes in DM group without DR, and in 4 (33%) and 7 (58%) in DM group 
with mild non-proliferative DR. 
 
Summary statistics of IRCT thickness in the three groups is presented in table 2. 
  
  Nasal IRCT1 Nasal IRCT2 
Temporal 
IRCT1 
Temporal 
IRCT2 
Control 
Mean 202 193 179 159 
Median 200 193 178 157 
SD 23 23 17 17 
Min 164 143 136 120 
Max 252 244 224 200 
DM without 
DR 
Mean 198 187 171 151 
Median 192 187 171 152 
SD 24 15 14 14 
Min 167 157 144 124 
Max 248 215 193 186 
Mild non-
proliferative 
DR 
Mean 191 198 170 155 
Median 195 198 166 158 
SD 24 16 14 12 
Min 149 160 152 132 
Max 226 216 197 171 
 
Table 2. IRCT1: Inner retinal complex thickness at 1000μm of the foveal centre; IRCT2: Inner 
retinal complex at 2000μm of the foveal centre. All the values expressed in μm. 
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Mean central macular thickness was 260±23 (205 to 294) in healthy eyes, 261±23 (224 to 315) 
in DM group without DR and 262±22 (224 to 292) in DM with mild non-proliferative DR. 
 
 
Comparisons between control and DM group without DR 
 
The studied characteristics of the 32 eyes with type 2 DM without DR were compared with the 
44 healthy eyes of 44 healthy volunteers with similar age and sex. No comparisons were made 
with the group with mild non-proliferative DR due to the reduced number of cases included in 
the study.  
 
When compared with control group, DM without DR underwent significant loss of ELM and 
IS/OS bulges (p<0.05; Chi2 test and p<0.01; Fisher’s exact test, respectively) but COST 
distribution was similar in both groups. 
 
Both, healthy and DM without DR, displayed significantly higher IRCT thickness in nasal than in 
temporal locations (p<0.001; paired t test) and measures at 1000 µm from the centre of the 
fovea were significantly higher than measures at 2000 µm (p<0.01; paired t test).   
 
The comparisons in equivalent locations between healthy and DM without DR showed no 
significant differences, except for temporal IRCT1. In this specific location DM without DR 
group displayed a slight but significant IRCT decrease (p<0.05; student’s t test) with a mean 
difference of 8 µm (95% confidence interval = 0.5-15 µm). 
 
No significant differences were found in central macular thickness between both groups. 
 
 
Visual acuity and Colour vision in DM patients 
 
The mean of BCVA was 0.82±0.16 in DM group without DR and 0.89±0.21 in DM group with 
mild non-proliferative DR. 
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By Ishihara test, no errors were displayed in the 90% of the cases in DM group without DR, 2 
patients had an error and 1 patient made 2 errors. No errors were displayed in DM group with 
mild non-proliferative DR. 
 
Summary statistics of Farnsworth-Munsell D-15 test for the two groups of DM is displayed at 
table 3. 
 
 
 
Number 
of errors 
SI CI Angle 
DM without 
DR 
Mean 2.5 1.7 1.60 32.6 
Median 2 1.6 1.61 62 
SD 2.82 0.42 0.57 57.2 
Min 0 1.11 1 -83.9 
Max 11 2.78 2.97 81.4 
Mild non-
proliferative 
DR 
Mean 2.4 1.8 1.6 40 
Median 2 1.6 1.63 62 
SD 2.5 0.51 0.52 57.2 
Min 0 1.4 1 -83.9 
Max 9 3.2 2.3 89.6 
 
Table 3. SI: Selectivity index (quantifies the amount of polarity or lack of randomness in a cap 
arrangement); CI: Confusion Index (quantifies the degree of colour loss relative to a perfect 
arrangement of caps); Angle (identifies the type of colour defect) 
 
Comparisons of the visual acuity among DM eyes without DR with different COST classification 
and presence/absence of ELM and IS/OS dome-shaped appearance were carried out. 
Significant differences were only found between eyes with COST=2 and eyes with COST=0 
(p=0.035; ANOVA). The mean difference in BCVA in this comparison (COST=2 vs COST=0) was 
0.78 with a 95% confidence interval from 0.98 to 0.62. 
 
No comparisons of colour vision tests results were made because of the reduced number of 
errors found in the DM group without DR. 
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DISCUSSION 
 
The results of this study showed that type 2 DM patients without signs of DR have anatomical 
changes at foveal level. IRCT seems to keep the normal relationship between nasal and 
temporal thickness but temporal location near the centre of the fovea could tend to be 
thinner than in normal eyes. The COST distribution was similar in both groups, but significant 
differences in BCVA were found between DM eyes with COST=2 and COST=0. 
 
Our results showed no differences between control and DM group at the COST layer. This may 
be because this layer is difficult to discriminate, and its categorization is less reliable (it would 
be expected that all control group had COST = 2). However, at DM group without DR we seen 
significant differences between BCVA according to COST classification. Tendency to the lack of 
COST seems to induce visual acuity lost. 
 
No others morphological changes seems to be determinants to BCVA neither colour vision. 
Nevertheless, it is worth mentioning that sample size was calculated to detect changes at FB 
level, but not to detect if other changes may be determinants of BCVA or colour vision. A big 
sample may be necessary to get more conclusive results in this part of our aim. 
 
There is evidence suggesting that photoreceptors contribute to vascular disease in diabetic 
retinopathy.11 Two hypotheses have been raised: hypoxia and oxidative stress.12 Our results 
agree with some studies with animals reporting that, at least, some photoreceptors 
degenerate early in the course of diabetes. A study in diabetic-induced rodents show an 
increased basement membrane thickness in diabetic retina.14 Park et al15 found a slight 
reduction in the thickness of the inner retina and a remarkable reduction in the outer nuclear 
layer 24 weeks after the inset of diabetes.  
 
There are few studies with patients. Occasional case reports suggest photoreceptor loss in 
diabetes or DME,16 but there has been no systematic demonstration that photoreceptors are 
lost in diabetic patients, with the exception of autopsy evidence showing that the S-cones 
selectively are lost in DR.17 Some studies related less severe morphological changes with visual 
loss in diabetic patients,18,10  but it is most studied in DME. IS/OS and ELM have been 
identified as useful parameters for optical coherence tomography evaluation of foveal 
 12 
 
photoreceptor layer integrity in DME.18,19 In DME, photoreceptor outer segment length of the 
central subfield was less10 than the mean cone OS length in the fovea of healthy subjects,20 
suggesting shortening of the photoreceptor outer segment length in diabetes or macular 
oedema. 
 
Two studies have analyzed the involvement of photoreceptors in patients with different DR 
severity in type 2 DM. Murakami9 evaluate the association between visual acuity with 
pathologic changes in morphology, macular thickness, and the status of ELM in DR, visualized 
by Spectralis OCT. They classified 3 types: cystoid macular oedema (CME), serous retinal 
detachment (SRD) absence of either (diffuse type). They found that the intact ELM might 
represent better visual acuity in eyes with the CME type and diffuse type but not in eyes with 
the SRD type in DR. CME type and diffuse type, a disrupted ELM or parafoveal thickening was 
significantly correlated with poor visual acuity. Jain13 correlate the serum levels of VEGF and 
intercellular adhesion molecule-1 (ICAM-1) with the severity of retinopathy and disruption of 
the ELM and IS/OS junction in type 2 DM. They classified 3 types: diabetes patients without 
retinopathy, with non-proliferative diabetic retinopathy, and with proliferative diabetic 
retinopathy. Their study showed that disruption of the ELM occurred even before disruption 
of the photoreceptor IS/OS junction. They hypothesized that increases in the level of diabetic 
retinopathy resulted in decreased biological activity of the ELM and IS/OS junction, which in 
turn resulted in the disruption of these layers and a decrease in visual acuity. An increase in 
serum VEGF and ICAM-1 levels is associated with an increase in the severity of diabetic 
retinopathy and the grade of ELM and IS-OS junction disruption. 
 
A histological study by Nork21 whit different techniques showed and widespread loss of the S-
cones in retinal detachment and diabetic retinopathy, which means that acquired tritan-like 
colour vision loss could be caused by selective loss of the S-cones. Greenstein et al22 study also 
studied about the sensitivity of the S-cone (blue) in retinal disease: retinitis pigmentosa, 
insulin-dependent DM and open-angle glaucoma. All of them showed a greater loss in 
sensitivity of an S than an M cone, however, the diabetic patients showed a more selective 
loss. These results suggest that multiple factor may be involved and that the combined effects 
of metabolic abnormalities and hypoxia contribute to the selective loss. 
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In conclusion, for the first time, we found that type 2 DM patients without DR or any other 
clinical retinal complication could tend to loss FB. This early alteration in central cone 
membranous discs might be related to the pathogenesis of DM.  IRCT in type 2 DM patients 
without DR seems to keep the normal relationship between nasal and temporal thickness but 
temporal location near the centre of the fovea could tend to be thinner than in normal eyes. It 
may be an early sign of DR or diabetic polyneuropathy. Further studies are needed to better 
understand pathogenesis of anatomical changes in the photoreceptors and their relationship 
with diabetic retinopathy. 
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LEGENDS FOR DISPLAY ITEMS 
 
Tables 
 
Table 1. Distribution COST category in the three groups. 
 
Table 2. IRCT1: Inner retinal complex thickness at 1000μm of the foveal centre; IRCT2: Inner 
retinal complex at 2000μm of the foveal centre. All the values expressed in μm. 
 
Table 3. SI: Selectivity index (quantifies the amount of polarity or lack of randomness in a cap 
arrangement); CI: Confusion Index (quantifies the degree of colour loss relative to a perfect 
arrangement of caps); Angle (identifies the type of colour defect) 
 
Figures 
 
Figure 1. Spectral domain optical coherence tomography (OCT) showing the foveal bulge (FB) 
categories. A and B showed category 2 at external limiting membrane (ELM), inner segment / 
outer segment junction (IS/OS) and cone outer segment tips (COST). A shows presence of 
dome-shape appearance in both, ELM and IS/OS, and B shows absence of this foveal 
characteristics. 
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Video: How to improve your graphs and tables >> 
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print will be charged a fee to cover the cost of printing. Refer to the specific journal’s 
instructions for authors for more information. 
Alternatively, authors are encouraged to supply colour illustrations for online publication and 
black and white versions for print publication. Colour publication online is offered at no 
charge, but the figure legend must not refer to the use of colours. 
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File types 
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minimum resolution of 300 dpi is required, except for line art which should be 1200 dpi. 
Histograms should be presented in a simple, two-dimensional format, with no background 
grid. 
During submission, ensure that the figure files are labelled with the correct File Designation of 
“Mono Image” for black and white figures and “Colour Image” for colour figures. 
Figures are checked using automated quality control and if they are below the minimum 
standard you will be alerted and asked to resupply them. 
Please ensure that any specific patient/hospital details are removed or blacked out (e.g. X-
rays, MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are NOT 
accepted. 
 
Tables 
Tables should be in Word format and placed in the main text where the table is first cited. 
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or figures. Any tables submitted that are longer/larger than 2 pages will be published as online 
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Authors are responsible for the accuracy of cited references and these should be checked 
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References must be numbered sequentially as they appear in the text. References cited in 
figures or tables (or in their legends and footnotes) should be numbered according to the 
place in the text where that table or figure is first cited. Reference numbers in the text should 
be inserted immediately after punctuation (with no word spacing)—for example,[6] not [6]. 
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are translated during the production process to superscript type, and act as hyperlinks from 
the text to the quoted references in electronic forms of the article. 
Please note that if references are not cited in order the manuscript may be returned for 
amendment before it is passed on to the Editor for review. 
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References must be numbered consecutively in the order in which they are mentioned in the 
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Only papers published or in press should be included in the reference list. Personal 
communications or unpublished data must be cited in parentheses in the text with the 
name(s) of the source(s) and the year. Authors should request permission from the source to 
cite unpublished data. 
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List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and 
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A DOI is a unique string created to identify a piece of intellectual property in an online 
environment and is particularly useful for articles that are published online before appearing 
in print (and therefore have not yet been assigned the traditional volume, issue and page 
number references). The DOI is a permanent identifier of all versions of an article, whether 
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Find a DOI >> 
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All supplementary files should be uploaded using the File Designation "Supplementary File". 
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local language, which are published online only alongside the English version. These should be 
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Statistics 
Statistical analyses must explain the methods used. 
Guidelines on presenting statistics >> 
 
Research reporting guidelines 
Authors are encouraged to use the relevant research reporting guidelines for the study type 
provided by the EQUATOR Network. This will ensure that you provide enough information for 
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comments? 
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